Key facts
- This page summarizes Amy Banse's Form 4 filing for CLOROX CO /DE/ (CLX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Oct 2024, 18:32.
Amy Banse - 30 Sep 2024 Form 4 Insider Report for CLOROX CO /DE/ (CLX)
- Reporting relationship
- Director
- Issuer ticker
- CLX
- Reported as of
- 30 Sep 2024
- Net transaction value
- +$26,229
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2024, 18:32:53 UTC
- Prior SEC filing
- 03 Sep 2024
- Next SEC filing
- 02 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- By Cheryl Brice, Attorney-in-Fact for
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amy Banse filed Form 4 for CLOROX CO /DE/ (CLX) on 02 Oct 2024.
Change
- Previous filing in this sequence was filed on 03 Sep 2024.
- Current net transaction value: +$26,229.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLX
transaction
Common Stock
Award
- Transaction value
- $26,229
- Shares
- +161
- Change %
- +44%
- Price
- $162.91
- Shares after
- 524
- Date
- 30 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLX
transaction
Derivative
Deferred Stock Units
Award
- Transaction value
- $0
- Shares
- +61
- Change %
- +0.77%
- Price
- $0.000000
- Shares after
- 8,031
- Date
- 30 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61
- Exercise price
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Receipt of Common Stock in lieu of quarterly director's fee.
Footnote F2
1-for-1
Footnote F3
Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.
Footnote F4
The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.